vs
Side-by-side financial comparison of Hoyne Bancorp, Inc. (HYNE) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $3.6M, roughly 1.8× Hoyne Bancorp, Inc.). Hoyne Bancorp, Inc. runs the higher net margin — 1.9% vs -303.5%, a 305.4% gap on every dollar of revenue.
Hoyne Bancorp, Inc. is a U.S.-based financial holding company operating through its banking subsidiary. It offers retail and commercial banking services including deposits, lending products, wealth management solutions, and personalized financial support to individual consumers, small and medium-sized businesses, and local community clients across its regional footprint.
HYNE vs PRLD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.6M | $6.5M |
| Net Profit | $70.1K | $-19.7M |
| Gross Margin | — | — |
| Operating Margin | 2.6% | -314.1% |
| Net Margin | 1.9% | -303.5% |
| Revenue YoY | — | 116.7% |
| Net Profit YoY | — | 38.9% |
| EPS (diluted) | — | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $3.6M | $6.5M | ||
| Q3 24 | — | $3.0M |
| Q3 25 | $70.1K | $-19.7M | ||
| Q3 24 | — | $-32.3M |
| Q3 25 | 2.6% | -314.1% | ||
| Q3 24 | — | -1145.9% |
| Q3 25 | 1.9% | -303.5% | ||
| Q3 24 | — | -1075.7% |
| Q3 25 | — | $-0.26 | ||
| Q3 24 | — | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $55.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $90.1M | $58.5M |
| Total Assets | $454.8M | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $55.0M | ||
| Q3 24 | — | $153.6M |
| Q3 25 | $90.1M | $58.5M | ||
| Q3 24 | — | $156.4M |
| Q3 25 | $454.8M | $94.8M | ||
| Q3 24 | — | $197.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.0K | $-19.1M |
| Free Cash FlowOCF − Capex | $-463.0K | — |
| FCF MarginFCF / Revenue | -12.7% | — |
| Capex IntensityCapex / Revenue | 12.0% | 0.0% |
| Cash ConversionOCF / Net Profit | -0.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-25.0K | $-19.1M | ||
| Q3 24 | — | $-27.3M |
| Q3 25 | $-463.0K | — | ||
| Q3 24 | — | $-27.4M |
| Q3 25 | -12.7% | — | ||
| Q3 24 | — | -912.0% |
| Q3 25 | 12.0% | 0.0% | ||
| Q3 24 | — | 2.1% |
| Q3 25 | -0.36× | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
